NCT00791999 - Efficacy Confirmation Trial of CDP870 as add-on Medication to Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA) | Biotech Hunter

Enrollment

316

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2011

Conditions

Rheumatoid Arthritis

Interventions

DRUG

CDP870 400mg

400mg CDP870 given every 2 weeks until Week22 (SC)

DRUG

CDP870 200mg

400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2 weeks until Week22 (SC)

DRUG

CDP870 100mg

200mg CDP870 given at Week0, 2, 4 and thereafter 100mg CDP870 given every 2 weeks until Week22 subcutaneously(SC)

DRUG

Placebo of CDP870

given every 2 weeks until Week22 (SC)

Trial Locations (8)

Chubu Region

Chugoku Region

Hokkaido Region

Kanto Region

Kinki Region

Kyushuh Region

Shikoku Region

Tohoku Region